| answer text |
<p>Since the beginning of the pandemic, the UK has championed the importance of rapid,
equitable access to safe and effective vaccines. We are among the largest donors to
the COVAX Advance Market Commitment (AMC), committing £548 million. Through match-funding,
this leveraged $1 billion from other donors in 2020. This support to COVAX has been
critical to its distribution of over 136 million COVID-19 vaccines to over 136 countries
and economies, with its aim to provide up to 1.8 billion doses to low and middle-income
countries by early 2022. The UK has also committed to sharing 100 million vaccine
doses by June 2022, 80 per cent of which will go to COVAX to provide further support
for countries in need.</p><p>The UK's financial commitment to COVAX contributes to
the whole COVAX portfolio, which currently consists of 11 COVID-19 vaccines. Exact
numbers of different vaccines supplied to countries will depend on timing of availability,
country demand and preferences, overall portfolio mix, and ongoing assessment and
guidance from the World Health Organisation (WHO) on vaccine effectiveness as the
evidence base for different vaccines continues to evolve. All vaccines disbursed by
COVAX must pass robust WHO Emergency Use Listing (EUL) or full pre-qualification assessment.</p>
|
|
